Fundraising Fox
/Companies
Sign in

CrossBridge Bio

Houston, US · Founded 2023 · United States corporation · 3 known investors

Find your way into CrossBridge Bio

Sign up to see every warm intro you have to CrossBridge Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the CrossBridge Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications. The company originated from ADC technology developed at the University of Texas Health Science Center at Houston.

BiotechHealthtech

Founders & leadership

CrossBridge Bio was founded in 2023 by Kyoji Tsuchikama and Michael Torres.

KTKyoji Tsuchikama
Kyoji TsuchikamaCo-founder
MTMichael Torres
Michael TorresCo-founder

Board

WFWilliam F. McKeon
William F. McKeonBoard directorInvestor at TMC Venture Fund
DI
Damir IllichBoard director
PJ
Patrick James CrutcherBoard director

Investors · 3

TMC Venture Fundlisted by TMC Venture FundHouston

How we know: TMC Venture Fund's portfolio page · funding news · Not right? Tell us

Portalreported

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$10.8M disclosed across 1 of 2 rounds · 2024–2026

▶$10.8MraisedNov 2024 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William F. McKeonDirector
  • Kyoji TsuchikamaExecutive Officer, Director, Promoter
  • Damir IllichDirector
  • Patrick James CrutcherDirector
  • Michael TorresExecutive Officer, Director, Promoter
  • Zhiqiang AnPromoter
Offering amount
$17M
Amount sold
$10.8M
First sale
Oct 2024
Incorporated
Corporation, United States, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
ImmuneBridgeImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
FiveableFiveable provides AI-powered exam preparation for AP classes, offering practice questions with automated scoring and personalized study tools for high school students.

Companies working in the same space as CrossBridge Bio.

In the news

CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies - BioSpacebiospace.com · Nov 2024CrossBridge Bio Raises $10M in Fundingfinsmes.com · Nov 2024

Frequently asked questions

What does CrossBridge Bio do?
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications. The company originated from ADC technology developed at the University of Texas Health Science Center at Houston.
Who founded CrossBridge Bio?
CrossBridge Bio was founded by Kyoji Tsuchikama, Michael Torres in 2023.
Who are CrossBridge Bio's investors?
CrossBridge Bio's investors include Portal Innovations, TMC Venture Fund, Portal.
How much funding has CrossBridge Bio raised?
CrossBridge Bio has disclosed $10.8M raised across 1 of its 2 known rounds.
Where is CrossBridge Bio headquartered?
CrossBridge Bio is headquartered in Houston, US.